Last reviewed · How we verify
Nebivolol Pill
Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while preserving vasodilatory properties through nitric oxide release.
Nebivolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure while preserving vasodilatory properties through nitric oxide release. Used for Hypertension, Heart failure with reduced ejection fraction, Angina pectoris.
At a glance
| Generic name | Nebivolol Pill |
|---|---|
| Sponsor | Tartu University Hospital |
| Drug class | Beta-1 selective adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nebivolol blocks beta-1 adrenergic receptors on the heart, decreasing heart rate and contractility to lower blood pressure and reduce cardiac workload. Unlike non-selective beta-blockers, it has additional vasodilatory effects mediated by nitric oxide release in endothelial cells, which may provide additional cardiovascular benefits and improved tolerability.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Angina pectoris
Common side effects
- Fatigue
- Dizziness
- Headache
- Bradycardia
- Hypotension
Key clinical trials
- Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension (PHASE4)
- Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism (EARLY_PHASE1)
- The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker (PHASE4)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Safety Study of Nebivolol for COPD Patients (PHASE2, PHASE3)
- Influence of Nebivolol on Postmenopausal Women
- Nebivolol in the Supine Hypertension of Autonomic Failure (NA)
- Nebivolol Effects on Endothelial Function and Erectile Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebivolol Pill CI brief — competitive landscape report
- Nebivolol Pill updates RSS · CI watch RSS
- Tartu University Hospital portfolio CI